Pulmonx (NASDAQ:LUNG) Posts Earnings Results, Beats Expectations By $0.07 EPS

Pulmonx (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07, Zacks reports. The business had revenue of $18.85 million for the quarter, compared to analyst estimates of $17.54 million. Pulmonx had a negative net margin of 88.60% and a negative return on equity of 46.63%. During the same quarter in the prior year, the business posted ($0.42) EPS. Pulmonx updated its FY 2024 guidance to EPS.

Pulmonx Stock Up 21.5 %

LUNG stock traded up $1.66 during midday trading on Thursday, hitting $9.38. The company’s stock had a trading volume of 1,221,082 shares, compared to its average volume of 514,849. The firm has a 50-day simple moving average of $8.65 and a 200-day simple moving average of $10.69. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. Pulmonx has a 52-week low of $7.11 and a 52-week high of $14.84. The firm has a market capitalization of $361.51 million, a P/E ratio of -5.86 and a beta of 0.66.

Insider Buying and Selling at Pulmonx

In related news, insider Geoffrey Beran Rose sold 3,097 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $28,058.82. Following the completion of the sale, the insider now owns 239,952 shares in the company, valued at approximately $2,173,965.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Glendon E. French III sold 6,954 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $63,003.24. Following the sale, the chief executive officer now owns 1,116,758 shares of the company’s stock, valued at approximately $10,117,827.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Geoffrey Beran Rose sold 3,097 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $28,058.82. Following the completion of the sale, the insider now owns 239,952 shares in the company, valued at $2,173,965.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,032 shares of company stock valued at $469,012. Insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LUNG. Citigroup increased their price target on Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Piper Sandler reiterated an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research report on Wednesday, April 3rd. Stifel Nicolaus lifted their price target on Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price objective (down from $16.00) on shares of Pulmonx in a research note on Friday, February 23rd. Finally, Canaccord Genuity Group dropped their target price on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.33.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.